Microbiome

This is the latest episode of the free DDW narrated podcast, “Outside the box thinking for drug discovery success”, which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Stanford researchers construct the most complete synthetic microbiome, Highs and lows of drug repurposing, and Unlocking the potential of mucoadhesive drug […]

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in a transaction valued at approximately […]

By Katie Gillette, Senior Project Leader, Eliza French, Analyst, Graham Friedman, Analyst, and Olivia Qiu, Associate, DeciBio.  Earlier this year, we explored the microbiome and its role in drug development across various therapeutic areas. This article will focus on one such area of great unmet need and promise: women’s health. We will explore the various […]

An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. The human microbiome refers to the vast array of microorganisms that live in and on the human body. With […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use […]

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether it be a monoclonal antibody to treat peanut allergy, or using […]

A new study has revealed consistent biological signals in the human microbiome and other physiological signals associated with autism. The research highlights the need for long-term studies to determine autism’s underlying causes. Taking a new computational approach to the problem, a study published in Nature Neuroscience has shed new light on the relationship between the […]

This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the age of spatial biology”, “Exploiting the microbiome to drive nature – inspired innovation”, […]

Microbiome research company Clinical Microbiomics has acquired MS-Omics, a leading provider based in Denmark.   With this acquisition, Clinical Microbiomics hopes to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.    Anders Grøn, CEO at Clinical Microbiomics, commented: “There is an unmet need in the […]

Listen to this article on the DDW Podcast: Rebecca McClellan, Scientific Program Manager, Research, Development & Communications, explains how scientists are learning more about the connections between the microbiome and human health to potentially develop first-in-class microbiome therapies. Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial […]

Listen to this article on the DDW Podcast: Exploitation of microbiome science will unlock multiple commercial opportunities across a number of industries including life sciences. But there is a need for more effective data and process management to get the best from microbiome data, according to Dr Sven Sewitz, Director of Biodata Innovation at Eagle Genomics. […]

Microba Life Sciences, a precision microbiome science company based in Australia, showcased its therapeutic platform and discovery platform for the identification of novel microbial signatures at Microbiome Movement, a European drug development summit, on January 27.  The event  The event brought together researchers from the biopharmaceutical industry to discuss the latest scientific discoveries and development progress, […]

Microba technology has been used for microbiome analysis to unlock diagnostic applications. This has led to the company receiving ISO15189 accreditation for a new untargeted NGS based assay of stool samples. This makes the company the first Australian microbiome company granted ISO15189 accreditation by NATA (The National Association of Testing Authorities, Australia).  Microba’s testing method  The hypothesis-free […]

In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers.  The study  With samples taken before, during, and after intensive training, […]

4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021.  The study  The Phase II study was […]

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 […]